Synaptic density in the central nervous system can be measured in vivo using PET with [18F]SynVesT-1. While [18F]SynVesT-1 has been proven to be a powerful radiopharmaceutical for PET imaging of neurodegenerative disorders such as Parkinson’s disease (PD), its currently validated acquisition and quantification protocols are invasive and technically challenging in these populations due to the arterial sampling and relatively long scanning times. The objectives of this work were to evaluate a noninvasive (reference tissue) quantification method for [18F]SynVesT-1 in PD patients and to determine the minimum scan time necessary for accurate quantification. [18F]SynVesT-1 PET scans were acquired in 5 patients with PD and 3 healthy control subjects for 120 min with arterial blood sampling. Quantification was performed using the one-tissue compartment model (1TCM) with arterial input function, as well as with the simplified reference tissue model (SRTM) to estimate binding potential ([ ]) using centrum semiovale (CS) as a reference region. The SRTM2 method was used with [ ] fixed to either a sample average value (0.037 min-1) or a value estimated first through coupled fitting across regions for each participant. Direct SRTM estimation and the Logan reference region graphical method were also evaluated. There were no significant group differences in CS volume, radiotracer uptake, or efflux ([ ]). Each fitting method produced [ ] estimates in close agreement with those derived from the 1TCM (subject [ ], [ ]), with no difference in bias between the control and PD groups. With SRTM2, [ ] estimates from truncated scan data as short as 80 min produced values in excellent agreement with the data from the full 120 min scans ([ ]). While these are preliminary results from a small sample of patients with PD ([ ]), this work suggests that accurate synaptic density quantification may be performed without blood sampling and with scan time under 90 minutes. If further validated, these simplified procedures for [18F]SynVesT-1 PET quantification can facilitate its application as a clinical research imaging technology and allow for larger study samples and include a broader scope of patients including those with neurodegenerative diseases.
[18F]SynVesT-1 is a PET radiopharmaceutical that binds to the synaptic vesicle protein 2A (SV2A) and serves as a biomarker of synaptic density with widespread clinical research applications in psychiatry and neurodegeneration. The initial goal of this study was to concurrently conduct PET imaging studies with [18F]SynVesT-1 at our laboratories. However, the data in the first two human PET studies had anomalous biodistribution despite the injected product meeting all specifications during the prerelease quality control protocols. Further investigation, including imaging in rats as well as proton and carbon 2D-NMR spectroscopic studies, led to the discovery that a derivative of the precursor had been received from the manufacturer. Hence, we report our investigation and the first-in-human study of [18F]SDM-4MP3, a structural variant of [18F]SynVesT-1, which does not have the requisite characteristics as a PET radiopharmaceutical for imaging SV2A in the central nervous system.
3 February 2025 in Biomedical Physics & Engineering Express
Objective. Arterial sampling for PET imaging often involves continuously measuring the radiotracer activity concentration in blood using an automatic blood sampling system (ABSS). We proposed and validated an external delay and dispersion correction procedure needed when a change in flow rate occurs during data acquisition. We also measured the external dispersion constant of [11C]CURB, [18F]FDG, [18F]FEPPA, and [18F]SynVesT-1. Approach. External delay and dispersion constants were measured for the flow rates of 350, 300, 180, and 150 ml h−1, using 1-minute-long rectangular inputs (n = 10; 18F-fluoride in saline). Resulting constants were used to validate the external delay and dispersion corrections (n = 6; 18F-fluoride in saline; flow rate change: 350 to 150 ml h−1 and 300 to 180 ml h−1); constants were modelled to transition linearly between flow rates. Corrected curves were assessed using the percent area-under-the-curve (AUC) ratio and a modified model selection criterion (MSC). External delay and dispersion constants were measured for various radiotracers using a blood analog (i.e., similar viscoelastic properties). Main results. ABSS outputs were successfully corrected for external delay and dispersion using our proposed method accounting for a change in flow rate. AUC ratio reduced from ∼10% for the uncorrected 350–150 ml h−1 output (∼6% for the 300–180 ml h−1) to < 1% after correction when compared to true input (511 keV energy window); approx. 5-fold increase in MSC. Assuming an internal dispersion constant of 5 s, the dispersion constant (internal + external) for [11C]CURB, [18F]FDG, [18F]FEPPA, and [18F]SynVesT-1 was 13, 9, 16, and 10 s, respectively. Significance. This study presented an external delay and dispersion correction procedure needed when a change in flow rate occurs during ABSS data acquisition. Additionally, this is the first study to measure the external delay and dispersion constants using a blood analog solution, a suitable alternative to blood when estimating external dispersion.
5 March 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Purpose The suitability of the white matter centrum semiovale (CS) as a pseudo-reference region for simplified reference tissue model 2 (SRTM2) with [¹⁸F]SynVesT-1 PET has not been evaluated in youth cohorts. We aimed to assess noninvasive quantification methods and determine the minimum scan time needed in a sample of youth with mental health challenges. Methods Thirty-five youth participants (16–25 years old) from the Toronto Adolescent & Youth cohort underwent 120-minute scans with arterial sampling. Binding potential (BPND) was estimated using one-tissue compartment model (1TCM) as a reference method. The SRTM2 was then applied, with k2′ parameter either set to population average (k2 from 1TCM) or estimated individually by initial coupled fitting in a two-step procedure. Standardized uptake value ratio − 1 (SUVR − 1, 60–90 min) was compared with 1TCM-derived BPND. Linear regression and percent bias analyses were performed. Time stability was assessed using several truncated scans (40–100 min). Results CS volume (1.7 ± 0.2 mL), VT (4.0 ± 0.6 mL/cm3) and k2 (0.031 ± 0.004 min− 1) were consistent with previously reported values. The population-based k2′ (0.031) and SUVR − 1 closely matched 1TCM results (R2 > 0.9, < 5% mean bias). The coupled-k2′ approach underestimated several regions (R2 > 0.9, > 10% bias in some regions). Minimum scan durations were 60 min for 1TCM, 90 min for fixed-k2′, and ≥ 100 min for coupled-k2′. Conclusion The population-based k2′ and semiquantitative SUVR–1 provide accurate [¹⁸F]SynVesT-1 quantification in youth with diverse clinical symptoms, supporting their use as noninvasive methods, and allowing scan time reduction to 90 minutes. This will facilitate its clinical use and wider applicability.